ERBB2 and breast cancer: A population-based Dutch study of recurrence from operated non-metastatic breast cancer by molecular subtypes (Luminal A, Luminal B, HER2 positive and triple negative) which found at 10 years: 13% of luminal A, 23% of luminal B, 30% of HER2 positive and 27% of triple negative cancers to be recurrent, with a 10-year overall recurrence rate of 18% (over a 11.3 year median follow-up time) (32).